Navigation Links
India's Non-Small-Cell Lung Cancer Drug Market Will Almost Double by 2013
Date:5/13/2009

Western Branded Drug Sales Will Command 54 percent of the Market by 2013, According to a New Report from Decision Resources

WALTHAM, Mass., May 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in India will almost double by 2013, growing from $27.7 million in 2008 to $52.1 million in 2013. This growth will be fueled by an increased uptake of antimetabolites and targeted therapies. In fact, the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitor drug classes will dominate the market throughout the forecast period with a combined market share of 55 percent by 2013.

The new Emerging Markets report entitled Non-Small-Cell Lung Cancer in India also finds that Western-branded drug sales in India's non-small-cell lung cancer market will command 54 percent by 2013. Even though Western-branded small-molecule agents are facing fierce competition from domestic products, including gefitinib (in the U.S. known as AstraZeneca's Iressa) and erlotinib (in the U.S. known as Genentech's Tarceva), future opportunities for Western companies will depend heavily on their pricing strategies and their patent protection in India. Moreover, monoclonal antibodies will surge and won't be copied successfully during the report's 2008 - 2013 forecast period.

"Opportunity for Western companies penetrating or wanting to penetrate India's non-small-cell lung cancer (NSCLC) drug market lies in forming alliances with Indian companies in order to negotiate the complex regulatory process of getting new NSCLC therapies to market," stated Manashi Sherawat, Ph.D., analyst at Decision Resources. "Opportunity also lies in raising awareness of this form of cancer in India's urban and rural sectors."

About Emerging Markets Reports

Emerging Markets is a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
2. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
3. Survival differences by race most apparent in advanced stages of breast cancer
4. MRI finds breast cancer before it becomes dangerous
5. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
6. Pathway links inflammation, angiogenesis and breast cancer
7. Radiologists encouraged to look beyond cancer for clinically unseen diseases
8. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
9. Immune deficiency linked to a type of eye cancer
10. Drop in breast cancer incidence linked to hormone use, not mammograms
11. Breast cancer prevention practices vary across Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 2016 , ... Spring Fertility , the only fertility ... egg freezing, today announced the grand opening of its first location in San ... Fertility offers both fertility preservation (egg, sperm, embryo, and testicular and ovarian tissue ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... Wharton Seminars for Business Journalists , led by the Wharton School’s ... and economic issues.  This one-day program at the Wharton School’s San Francisco ...
(Date:5/5/2016)... ... May 05, 2016 , ... United Benefit Advisors (UBA), ... as the latest addition to its family of Partner Firms. Headquartered in Mount ... wellness, human resources, and health care consumerism specialists. , “Partnering with UBA will ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... Make-A-Wish grants the most heartfelt wishes of these children. The wishes provide ... treatment. President and CEO of Make-A-Wish Mississippi, Brent Wilson said, “In 2016, ...
(Date:5/5/2016)... ... May 05, 2016 , ... Michael Lanteri Agency ... created to assist the people of their local community. The agency pledges to ... community leaders. Their hope is to bring awareness to important local causes with ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... Research and Markets has ... Ischemic Stroke Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Ischemic Stroke epidemiology, Acute Ischemic ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Actinic Keratosis Market ... to their offering.       (Logo: ... Keratosis Market and Competitive Landscape Highlights 2016, ... products, Actinic Keratosis epidemiology, Actinic Keratosis market ...
(Date:5/3/2016)... 4, 2016 Global Insulin ... profiling 09 key companies and supported with 272 ... in-depth study on the current state of the ... the industry including definitions, classifications, applications and industry ... provided for the international market including development history, ...
Breaking Medicine Technology: